قالب وردپرس درنا توس
Home / Health / NorCal scientists developed COVID-19 nasal spray, inhaler

NorCal scientists developed COVID-19 nasal spray, inhaler



Scientists and UC San Francisco have announced a protection against inhaled COVID-19 with the goal of being manufactured into an affordable, over-the-counter antiviral drug in the coming months. UCSF is working to initiate human trials on what they call “AeroNabs”. “This is a molecule that can bind to the extremely tightly bound coronavirus protein. And when it binds to the virus, it completely diffuses the ability to infect human cells, ”explained UCSF assistant professor and co-inventor Aashish Manglik. The COVID-19 virus has mutant proteins that bind to cell receptors, becoming hosts for newer coronaviruses and infection. “I like to think of it as a molecular mousetrap,”

; Manglik said. “It clamps down on the virus, keeps it from spreading – and that’s basically this.” Manglik was able to turn AeroNab into an aerosol, which can then be used as a nasal spray or as an inhaler. “Really, the hope for what we’re developing is to act as a bridge until we have a widely deployable vaccine that can be used by the masses,” Manglik said. majority of people. “People like nursing home residents or health care workers, or the people in meat packaging factories – things like that. People at high risk can take this molecule once a day as an inhaler or a nasal spray. “UCSF said the team is in active discussion with commercial partners for clinical trial and production. “Even with a vaccine, having it working is one thing, having it on a large scale is another. And then, enduring immunity to a large portion of the population with a vaccine, ”Manglik said. “And there may be some parts of the population that cannot tolerate the vaccine or the effects of the vaccine decrease more rapidly.”

Scientists and UC San Francisco have announced a protection against inhaled COVID-19 with the goal of being manufactured into an affordable, over-the-counter antiviral drug in the coming months.

UCSF is working to initiate human trials on what they call “AeroNabs”.

“This is a molecule that can bind to the extremely tightly bound coronavirus protein. And when it binds to the virus, it completely diffuses the ability to infect human cells, ”explained UCSF assistant professor and co-inventor Aashish Manglik.

The COVID-19 virus has mutant proteins that bind to cell receptors, becoming hosts for newer coronaviruses and infection.

“I like to think of it as a molecular mousetrap,” Manglik said. “It clamps down on the virus, keeps it from spreading – and this is basically the thing.”

Manglik was able to turn AeroNab into an aerosol, which can then be used as a nasal spray or as an inhaler.

“Really, the hope for what we’re developing is to act as a bridge until we have a widely deployable vaccine that can be used by the masses,” Manglik said. majority of people. “People like nursing home residents or health care workers, or the people in meat packaging factories – things like that. People at high risk may take this molecule perhaps once a day in the form of an inhaler or a nasal spray. “

UCSF said the team is in active discussions with commercial partners for clinical trial and production.

“Even with a vaccine, having it working is one thing, having it on a large scale is another. And then, enduring immunity to a large portion of the population with a vaccine, ”Manglik said. “And there may be some parts of the population that cannot tolerate the vaccine or the effects of the vaccine decrease more rapidly.”


Source link